
HOLYPHARM
Our Semaglutide Oral Tablet represents a significant advancement in medication, leveraging our cutting-edge oral delivery technology. This technology facilitates effective oral absorption of biopharmaceuticals through a targeted delivery system. Additionally, our tablet utilizes a unique excipient technology that ensures both stabilization and enhanced penetration. This combination of targeted delivery and advanced excipient technology underscores our commitment to pioneering innovations in drug delivery, providing patients with a more effective and convenient therapeutic option..
Research Data
[Biovailability in Beagle Dog: Single-dose h2h PK study]

The AUC of BO-017 mg capsule is 12 times higher than the Rybelsus 7 mg tablet.
[Primate research data: Comparison of promate absorption after a single dose]
Item | Specification | Subject | Number | AVG Cmax (ng/ml) | AVG T1/2 (hours) | Bioavailability |
Rybelsus | 5 mg | normal | n=24 | 8.3 | 7.94 | 0.4~1%(3) |
Rybelsus | 7 mg | normal | n=6 | 4.37 | / | 0.4~1%(3) |
BO-01 | 7 mg | normal | n=5 | 62.6 | 51.6 | / |
(1)Originated from Rybelsus EMA NDA data
(2)In-house data
(3)Originated from Rybelsus FDA NDA data
BO-01 displayed~8 times higher than Rybelsus when concerning their single-dose Cmax.
BO-01 displayed~7 times higher than Rybelsus when concerning their single-dose T1/2.
3.Our Advantages:
From a Polypeptide molecule to an IND Product
A.Oral Semaglutide Delivery Technology:
l Fully independent intellectual property
l High bioavailability
l Low material cost
l Safe excipients
l Extended drug half-life
From a IND Product to a Launch Product
B.R&D Platform Advantage:
l Controlled aplification
l Validated delivery
l QC compliance
4.Project Cooperation
A.Product License-out
l Biosimilar polypeptide molecules
l 2.2/505(b)(2) development
l Licensing out at early/late clinical stage
B.Technique License-out
When considering technique license-outs, we offer a comprehensive approach that caters to client-specific needs and supports the development of Type 1 original drugs and client-owned polypeptides. Our licensing model includes structured agreements with milestone fees, ensuring collaborative advancement from initial stages through to regulatory milestones. This approach not only fosters innovation but also facilitates strategic partnerships aimed at accelerating the delivery of novel therapeutics to market.